News
4.1.3.1 Combination of ADCs and tyrosine kinase inhibitors (TKIs) TKIs, such as Lapatinib (targeting HER2 and EGFR) and Osimertinib (targeting EGFR), are used in cancers with specific mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback